Latest news with #ChaseKnickerbocker
Yahoo
3 days ago
- Business
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT
Bioventus Inc. (NASDAQ:BVS) is one of the . On August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc. (NASDAQ:BVS) and set a price target of $15.00. A doctor repairing a foot and ankle injury using the latest sports medicine techniques. The analyst gave the rating after Bioventus Inc. (NASDAQ:BVS) reported its fiscal Q2 results on August 6, with reported revenue of $147.7 million declining 2.4% and organic revenue advancing 6.2%. Diluted earnings per share for Q2 was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period. Bioventus Inc. (NASDAQ:BVS) also reported cash from operations of $25.9 million and non-GAAP earnings of $0.21 per share. Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. While we acknowledge the potential of BVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Craig-Hallum Initiates Coverage of Butterfly (BFLY) With a Buy Rating
Butterfly Network, Inc. (NYSE:BFLY) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Craig-Hallum analyst Chase Knickerbocker has initiated coverage of Butterfly Network, Inc. (NYSE:BFLY) with a Buy rating and a $3 price target, citing the company's disruptive position in the point-of-care ultrasound market. Butterfly's proprietary technology replaces traditional piezoelectric crystal-based ultrasound components with a chip-based semiconductor platform, allowing for a single probe to handle multiple imaging needs. This innovation not only reduces manufacturing complexity and cost, but also enables rapid software-driven improvements that set Butterfly apart from most handheld competitors. A doctor looking at a ultrasound system with a Compass software interface, demonstrating the sophistication of the device. The firm's outlook is underpinned by Butterfly's expanding direct-to-consumer (DTC) reach and a growing number of institutional partnerships, including leading health systems and academic centers. These relationships are expected to drive consistent hardware sales while building recurring revenue from software subscriptions. Butterfly Network's technology also places it at the forefront of healthcare's digital transformation. By combining advanced imaging with real-time data interpretation and cloud-based collaboration tools, the company is integrating AI into clinical workflows to enhance diagnostic speed and accuracy. While we acknowledge the potential of BFLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BFLY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Business Insider
17-05-2025
- Business
- Business Insider
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on scPharmaceuticals (SCPH – Research Report) on May 15 and set a price target of $12.00. The company's shares closed yesterday at $3.22. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Knickerbocker covers the Healthcare sector, focusing on stocks such as Ironwood Pharma, Harrow Health, and MiMedx Group. According to TipRanks, Knickerbocker has an average return of 3.3% and a 43.33% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $16.50 average price target, which is a 412.42% upside from current levels. In a report released on May 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
